Xspray Pharma
Market Cap
kr2.2b
Last Updated
2020/10/29 21:53 UTC
Data Sources
Company Financials +
Executive Summary
Xspray Pharma AB (publ) engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. More Details
Rewards
Risk Analysis
+ 1 more risk
Snowflake Analysis
Exceptional growth potential with adequate balance sheet.
Share Price & News
How has Xspray Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: XSPRAY's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-3.7%
XSPRAY
-5.4%
SE Biotechs
-6.0%
SE Market
1 Year Return
99.2%
XSPRAY
15.1%
SE Biotechs
6.2%
SE Market
Return vs Industry: XSPRAY exceeded the Swedish Biotechs industry which returned 15.1% over the past year.
Return vs Market: XSPRAY exceeded the Swedish Market which returned 6.2% over the past year.
Shareholder returns
| XSPRAY | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.7% | -5.4% | -6.0% |
| 30 Day | -19.6% | -18.6% | -6.3% |
| 90 Day | -33.2% | -6.4% | 1.7% |
| 1 Year | 99.2%99.2% | 15.9%15.1% | 8.0%6.2% |
| 3 Year | 286.8%286.8% | 32.0%29.3% | 22.4%9.3% |
| 5 Year | n/a | 42.0%34.6% | 45.6%17.4% |
Price Volatility Vs. Market
How volatile is Xspray Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
19 hours ago | Simply Wall St
What Is The Ownership Structure Like For Xspray Pharma AB (publ) (STO:XSPRAY)?3 weeks ago | Simply Wall St
Have Xspray Pharma AB (publ) (STO:XSPRAY) Insiders Been Selling Their Stock?1 month ago | Simply Wall St
Xspray Pharma AB (publ)'s (STO:XSPRAY) About To Shift From Loss To ProfitValuation
Is Xspray Pharma undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: XSPRAY (SEK128.5) is trading below our estimate of fair value (SEK4365.01)
Significantly Below Fair Value: XSPRAY is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: XSPRAY is unprofitable, so we can't compare its PE Ratio to the SE Biotechs industry average.
PE vs Market: XSPRAY is unprofitable, so we can't compare its PE Ratio to the Swedish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate XSPRAY's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: XSPRAY is overvalued based on its PB Ratio (6.2x) compared to the SE Biotechs industry average (4.9x).
Next Steps
Future Growth
How is Xspray Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
111.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XSPRAY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.5%).
Earnings vs Market: XSPRAY is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: XSPRAY's is expected to become profitable in the next 3 years.
Revenue vs Market: XSPRAY's revenue (67.9% per year) is forecast to grow faster than the Swedish market (3.4% per year).
High Growth Revenue: XSPRAY's revenue (67.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: XSPRAY's Return on Equity is forecast to be very high in 3 years time (58.3%).
Next Steps
Past Performance
How has Xspray Pharma performed over the past 5 years?
-54.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: XSPRAY is currently unprofitable.
Growing Profit Margin: XSPRAY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: XSPRAY is unprofitable, and losses have increased over the past 5 years at a rate of 54.9% per year.
Accelerating Growth: Unable to compare XSPRAY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XSPRAY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (15.2%).
Return on Equity
High ROE: XSPRAY has a negative Return on Equity (-15.66%), as it is currently unprofitable.
Next Steps
Financial Health
How is Xspray Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: XSPRAY's short term assets (SEK141.6M) exceed its short term liabilities (SEK19.2M).
Long Term Liabilities: XSPRAY's short term assets (SEK141.6M) exceed its long term liabilities (SEK3.6M).
Debt to Equity History and Analysis
Debt Level: XSPRAY is debt free.
Reducing Debt: XSPRAY has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XSPRAY has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if XSPRAY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Xspray Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate XSPRAY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate XSPRAY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if XSPRAY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if XSPRAY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of XSPRAY's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.8yrs
Average management tenure
CEO
Per Andersson (53 yo)
14.75yrs
Tenure
kr2,675,000
Compensation
Dr. Per Andersson Ph.D. has been the Chief Executive Officer of Xspray Pharma AB (publ) since 2006. Dr. Andersson serves as the Chief Executive Officer of Xspray Microparticles AB. Dr. Andersson joined XSp ...
CEO Compensation Analysis
Compensation vs Market: Per's total compensation ($USD302.51K) is about average for companies of similar size in the Swedish market ($USD414.13K).
Compensation vs Earnings: Per's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 14.75yrs | kr2.68m | 1.16% SEK 25.9m | |
| Co-Founder and Science Director | no data | no data | no data | |
| Chief Finance Officer | 1.42yrs | no data | 0.026% SEK 591.7k | |
| Vice President of Operations | no data | no data | no data | |
| Sales & Marketing Director | no data | no data | no data | |
| Chief of Research & Development | 2.75yrs | no data | 0.0070% SEK 157.9k |
2.8yrs
Average Tenure
56yo
Average Age
Experienced Management: XSPRAY's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 5.75yrs | kr155.00k | 0.17% SEK 3.8m | |
| Independent Chairman of the Board | 7.75yrs | kr280.00k | 0.27% SEK 6.0m | |
| Independent Director | 5.75yrs | kr125.00k | no data | |
| Independent Director | 3.75yrs | kr140.00k | no data | |
| Independent Director | 1.42yrs | kr140.00k | 0.023% SEK 526.1k | |
| Independent Director | 1.42yrs | kr140.00k | 0.026% SEK 578.5k |
4.8yrs
Average Tenure
57.5yo
Average Age
Experienced Board: XSPRAY's board of directors are considered experienced (4.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: XSPRAY insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13%.
Top Shareholders
Company Information
Xspray Pharma AB (publ)'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Xspray Pharma AB (publ)
- Ticker: XSPRAY
- Exchange: OM
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr2.240b
- Shares outstanding: 17.03m
- Website: https://www.xspraypharma.com
Number of Employees
Location
- Xspray Pharma AB (publ)
- Råsundavägen 12
- Solna
- Stockholm County
- 169 67
- Sweden
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| XSPRAY | OM (OMX Nordic Exchange Stockholm) | Yes | Share Capital | SE | SEK | Sep 2017 |
| 0GHZ | LSE (London Stock Exchange) | Yes | Share Capital | GB | SEK | Sep 2017 |
| 6XP | BST (Boerse-Stuttgart) | Yes | Share Capital | DE | EUR | Sep 2017 |
Biography
Xspray Pharma AB (publ) engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo, HyNap-Sora, and HyNap-Dasa. The company was form ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/29 21:53 |
| End of Day Share Price | 2020/10/29 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.